Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy
Advanced Healthcare Materials · 2023-07 · 12 (19)
DOI: 10.1002/adhm.202300260 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 20.03.2023. Verfasst von Yongjuan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, 450001, China. Hauptthemen laut MEDLINE: Immunity, Innate, Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 223 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Zhengzhou University.
Abstract (Originalsprache)
As the first line of host defense against pathogenic infections, innate immunity plays a key role in antitumor immunotherapy. The cyclic GMP‐AMP synthase (cGAS)‐stimulator of interferon genes (STING) (cGAS‐STING) pathway has attracted much attention because of the secretion of various proinflammatory cytokines and chemokines. Many STING agonists have been identified and applied into preclinical or clinical trials for cancer immunotherapy. However, the fast excretion, low bioavailability, nonspecificity, and adverse effects of the small molecule STING agonists limit their therapeutic efficacy and in vivo application. Nanodelivery systems with appropriate size, charge, and surface modification are capable of addressing these dilemmas. In this review, the mechanism of the cGAS‐STING pathway is discussed and the STING agonists, focusing on nanoparticle‐mediated STING therapy and combined therapy for cancers, are summarized. Finally, the future direction and challenges of nano‐STING therapy are expounded, emphasizing the pivotal scientific problems and technical bottlenecks and hoping to provide general guidance for its clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- The Center of Infection and Immunity, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- School of Pharmaceutical Sciences, Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, State Key Laboratory of Radiation Medicine and Protection, and College of Pharmaceutical Sciences, Soochow University, Su…
ORCID-Profile: Zhiyuan Zhong, Weijing Yang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Zhengzhou University
- Key Technologies Research and Development Program
Zitieren
APA
Li, Y., Li, X., Yi, J., Cao, Y., Qin, Z., Zhong, Z., & Yang, W. (2023). Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy. Advanced Healthcare Materials, 12(19). https://doi.org/10.1002/adhm.202300260
Vancouver
Li Y, Li X, Yi J, Cao Y, Qin Z, Zhong Z, et al. Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy. Advanced Healthcare Materials. 2023;12(19). doi:10.1002/adhm.202300260
BibTeX
@article{Li2023,
author = {Li, Yongjuan and Li, Xinyan and Yi, Jinmeng and Cao, Yongjian and Qin, Zhihai and Zhong, Zhiyuan and Yang, Weijing},
title = {Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {19},
doi = {10.1002/adhm.202300260}
}
EUVIMED